Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial Publisher Pubmed



Abbasirad F1 ; Shaygannejad V2, 3 ; Hosseininasab F1 ; Mirmosayyeb O2, 4 ; Mahaki B5, 6 ; Moayedi B1 ; Esmaeil N1, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences (IUMS), Isfahan, 81744, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, 81744, Iran
  3. 3. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81744, Iran
  4. 4. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, 14176, Iran
  5. 5. Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, 67148, Iran
  6. 6. Social Development, & Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, 67148, Iran
  7. 7. Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, 81744, Iran

Source: International Immunopharmacology Published:2021


Abstract

Interferon beta (IFN-β) has successfully been experimented with to treat multiple sclerosis (MS). However, patients sometimes do not respond effectively to treatment, and ‌adverse effects, including liver toxicity, accompany this therapy. ‌Accordingly, we decided to treat MS patients simultaneously with Silymarin (SM) as an immunomodulatory and hepatoprotective agent and IFN-β in a clinical trial study. Complete blood count (CBC), liver enzyme levels, and the serum concentration of inflammatory and anti-inflammatory cytokines were measured. Also, the frequency of immune cells was determined by flow cytometry. Liver enzyme levels were significantly lower in the intervention group (p < 0.05). The percentage of Th17 cells in the intervention group was significantly reduced compared to the placebo group (P < 0.001). Also, the frequency of Treg cells after treatment with SM plus IFN-β was significantly increased compared to the placebo group (p < 0.05). Furthermore, the IL-17 and IFNγ cytokine levels were significantly reduced in the intervention group (p < 0.05). Moreover, the levels of anti-inflammatory cytokines IL-10 and TGFβ were significantly increased in the intervention group (P < 0.05). Overall, the results provide novel and supplementary information on SM's notable immunoregulatory effects on inflammatory response and liver function in MS patients. Clinical Trial Identifier Number: IRCTID: IRCT20171220037977N1. © 2021 Elsevier B.V.
Related Docs
View other Related Docs
1. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
2. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
3. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
4. Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (Ms) Patients in Vitro, Inflammation (2019)
5. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
6. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
7. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
8. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (40)
Vahid Shaygannejad (35)
Other Related Docs
9. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
10. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)
11. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
12. Transplantation of Human Adipose-Derived Stem Cells Overexpressing Lif/Ifn-Β Promotes Recovery in Experimental Autoimmune Encephalomyelitis (Eae), Scientific Reports (2022)
13. The Immunoregulatory and Neuroprotective Effects of Human Adipose Derived Stem Cells Overexpressing Il-11 and Il-13 in the Experimental Autoimmune Encephalomyelitis Mice, International Immunopharmacology (2020)
14. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
15. Effects of Low Dose Methotrexate on Relapsing-Remitting Multiple Sclerosis in Comparison to Interferon Β-1Α: A Randomized Controlled Trial, Journal of Research in Medical Sciences (2011)
16. Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy, Immunopharmacology and Immunotoxicology (2014)
17. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
18. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
19. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
20. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
21. Efficacy of Adding Vitamin D Supplementation to Interferon Β-1 in Multiple Sclerosis, Journal of Isfahan Medical School (2016)
22. Effect of High Dose Vitamin D Intake on Interleukin-17 Levels in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Neuroimmunology (2015)
23. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
24. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
25. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
26. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
27. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
28. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
29. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
30. The Frequency of Varicella-Zoster Virus Infection in Patients With Multiple Sclerosis Receiving Fingolimod, Journal of Neuroimmunology (2019)
31. The Favorable Impacts of Silibinin Polyphenols As Adjunctive Therapy in Reducing the Complications of Covid-19: A Review of Research Evidence and Underlying Mechanisms, Biomedicine and Pharmacotherapy (2022)
32. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
33. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
34. Impaired Il-12- and Il-23-Mediated Immunity Due to Il-12Rβ1 Deficiency in Iranian Patients With Mendelian Susceptibility to Mycobacterial Disease, Journal of Clinical Immunology (2018)
35. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
36. Immunosuppressive Effect of Silymarin on Mitogen-Activated Protein Kinase Signalling Pathway: The Impact on T Cell Proliferation and Cytokine Production, Basic and Clinical Pharmacology and Toxicology (2013)
37. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
38. Immunomodulatory Effects of Silymarin in Patients With Β-Thalassemia Major, International Immunopharmacology (2013)
39. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
40. The Beneficial Effects of Vitamin D3 on Reducing Antibody Titers Against Epstein-Barr Virus in Multiple Sclerosis Patients, Cellular Immunology (2015)
41. Interferon-Beta-1Beta Protects Against Multiple Sclerosis-Induced Endothelial Cells Apoptosis, Frontiers in Bioscience - Elite (2012)
42. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
43. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
44. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
45. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
46. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
47. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
48. Evaluating the Effect of Adding Fish Oil to Fingolimod on Tnf-Α Il1β Il6, and Ifn-Γ in Patients With Relapsing-Remitting Multiple Sclerosis: A Double-Blind Randomized Placebo-Controlled Trial, Clinical Neurology and Neurosurgery (2017)
49. Revisiting the Antiviral Theory to Explain Interferon-Beta's Effectiveness for Relapsing Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
50. Research Paper: The Association Between Salt and Potassium Intake With Multiple Sclerosis, Caspian Journal of Neurological Sciences (2019)